secwatch.observer — SEC 8-K summary
======================================

Issuer:     TALPHERA, INC. (TLPH)
CIK:        0001427925
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001437749-23-008621
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AcelRx restates interim 2022 financials due to EPS error; divests DSUVIA to Alora for royalties and milestones
--------------------------------------------------------------------------------

- Non-reliance on Q2 and Q3 2022 financials due to EPS calculation error (two-class method for warrants); no impact on cash, revenue, or net income.
- Divests DSUVIA to Alora Pharmaceuticals; receives 15% royalty on commercial sales, 75% on DoD sales, and up to $116.5M in milestones.
- Cash and short-term investments $20.8M as of Dec 31, 2022; Q4 2022 net loss $7.5M ($1.00 per share) vs $7.9M ($1.24) in Q4 2021.
- Full-year 2022 DSUVIA net sales $1.8M, up 76% YoY; combined R&D and SG&A expenses $7.3M in Q4 2022.
- Niyad (nafamostat) EUA submission planned for Q2 2023; Fedsyra NDA submission by end of Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427925/000143774923008621/0001437749-23-008621-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427925/000143774923008621/acrx20230330_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-008621

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer